The GAVA Consensus Statement recommends that the decision to deliver VAS through mass campaigns be based on an analysis that weighs the risks and benefits. If a country has already done the risk analysis for a polio campaign, do they need to do a separate risk analysis for VAS?

Yes, they do. The administration of the oral polio vaccine is similar to that of VAS, so many of the same risks for COVID-19 transmission during service delivery exist for both services. However, the benefits of conducting a polio campaign will be different than the benefits of conducting a VAS campaign, so a separate risk benefit analysis should be completed for VAS.